<DOC>
	<DOCNO>NCT00996749</DOCNO>
	<brief_summary>This phase I trial study best way give omega-3 fatty acid treat patient advanced prostate cancer . Omega-3 fatty acid may slow disease progression may effective treatment patient advanced prostate cancer</brief_summary>
	<brief_title>Omega-3 Fatty Acids Treating Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . To conduct pilot study omega-3 polyunsaturated fatty acid ( PUFA ) ( omega-3 fatty acid ) supplementation group patient advanced prostate cancer ass dose omega-3 PUFA necessary achieve omega-6 -3 ratio 1:1 individual basis assess clinical impact omega-3 supplementation disease progression OUTLINE : Patients receive long-term omega-3 polyunsaturated fatty acid ( PUFA ) supplementation orally ( PO ) . After completion study treatment , patient follow 1 , 6 , 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Disease currently control androgen ablation therapy Androgen ablation expect continue least 1 year Has treat androgen ablation therapy least 1 month Stable decrease prostatespecific antigen ( PSA ) androgen ablation therapy Stable visible metastatic disease image Eastern Cooperative Oncology Group ( ECOG ) functional status 0 1 Eligible local intervention surgery radiation Increasing serum PSA hormonal ablation Radiographic evidence progression disease hormonal ablation Current history second malignancy Previously treat chemotherapeutic agent Previous history intermittent androgen therapy Gastrointestinal ( GI ) disease impact absorption nutrient</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>